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Abstract
Objective—Evidence on antipsychotic comparative effectiveness, regulatory warnings, and
formulary and other restrictions on antipsychotics may have influenced physician prescribing
behavior. This study measured changes in the degree to which physicians customize treatment
choices to individual patients and changes in physician preferences for specific agents following
these events.
Methods—The study used 2002-2007 data from IMS Health Xponent™ and the AMA on the
prescribing and characteristics of a longitudinal cohort of 7,399 physicians. Descriptive and
multivariable regression analyses of the concentration of prescribing (physician-level Herfindahl
index), and preferences for and likelihood of prescribing 2 first-generation antipsychotics and 6
second-generation antipsychotics adjusting for prescribing volume, specialty, demographics,
practice setting and education were conducted.
Results—Antipsychotic prescribing was highly concentrated at the physician-level, with a mean
unadjusted Herfindahl index of .33 in 2002 and .29 in 2007. Psychiatrists reduced the
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concentration of their prescribing more over time than did other physicians. High volume
psychiatrists had a Herfindahl that was half that of low-volume physicians in other specialties (.18
vs. .36), a difference that remained significant (p<.001) after adjusting for physician
characteristics. The share of physicians preferring olanzapine dropped from 29.9% in 2002 to
10.3% in 2007 (p<.001) while the share favoring quetiapine increased (from 9.4% to 44.5%, p<.
001). Few physicians (<5%) preferred a first-generation antipsychotic in 2002 or 2007.
Conclusions—Preferences for specific antipsychotics changed dramatically during this period.
While physician prescribing remained heavily concentrated, it did decrease over time, particularly
among psychiatrists.
Antipsychotics have been approved by the Food and Drug Administration (FDA) to treat
schizophrenia, bipolar disorder, major depression and other mental disorders that impose an
enormous morbidity and mortality burden(1, 2) and are used off-label for many other
indications(3). Physicians now face a choice of over 90 antipsychotic products (24
molecules and their reformulations). Six second-generation antipsychotics introduced
between 1989 and 2002 rapidly became first-line treatment for these conditions on the basis
of early claims that they were more effective and safer than first-generation antipsychotics.
Second generation antipsychotics continue to claim a majority of the market in spite of their
higher costs(4).
However, comparative effectiveness research released 10 to 15 years after second generation
antipsychotics were introduced indicates that they carry significant risks, and that, with the
exception of clozapine, they may be no more effective than first-generation antipsychotics.
For example, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), a
widely-cited study published in 2005 that compared four second generation antipsychotics
with one first-generation antipsychotic in patients with schizophrenia, found few differences
among the drugs on all-cause discontinuation rates, the trial's primary measure of
effectiveness. Notably, CATIE also found that the risk of adverse effects and reason for
discontinuation differed widely between classes (second generation vs. first-generation), and
among second generation antipsychotics(5).
While CATIE findings remain controversial(6, 7) one might nevertheless expect physicians
to have changed their antipsychotic prescribing in response to it and other studies(8). Even
before CATIE, the FDA issued safety warnings in 2003 and 2005(9),(10) in response to
earlier studies pointing to risks(11) and consensus statements emphasized heterogeneous
risk profiles across second generation antipsychotics(12). Prescribing preferences are also
shaped by formularies and utilization management tools (13, 14), and some payers placed
restrictions on some second generation antipsychotics during this period.(15, 16) Prescribers
may have switched their preferred antipsychotic agent or stopped prescribing certain drugs
in response to these changes. However, little is known about whether new evidence or
changes in policy led clinicians to diversify their prescribing (17, 18). Studies of prescribing
for depression and bipolar disorder indicate that physicians rely heavily on preferred
agents(19-24) One study examined the degree of concentration in antipsychotic prescribing
but results were reported at the facility, not at the provider-level, for a single year(25). We
are aware of no studies that have examined changes over time in the degree of concentration
of antipsychotic prescribing. In this study, we measured changes in physician antipsychotic
prescribing behavior using data from a longitudinal cohort of physicians from multiple
specialties between 2002 and 2007.
Methods
We used monthly physician-level data from IMS Health's Xponent™ database on the
number of prescriptions dispensed for each first generation antipsychotic and second
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generation antipsychotic between January 2002 and December 2007. Xponent™ directly
captures over 70% of all U.S. prescriptions filled in retail pharmacies and utilizes a patented
proprietary projection methodology to represent 100% of prescriptions filled in these outlets.
Prescribing data were available for a 10% nationally-representative sample of physicians
from ten specialties with the highest antipsychotic prescribing volume (internal medicine,
general practice, family medicine, family practice, pediatrics, psychiatry, geriatric
psychiatry, child and adolescent psychiatry, neurology, and child neurology) (n = 24,206).
We limited the 10% sample to a longitudinal cohort of physicians who regularly prescribed
antipsychotics (i.e., at least 20 dispensed antipsychotic prescriptions) both in 2002 and in
2007. Our rationale is that very low volume prescribers tell us little about the diversity of a
physician's prescribing. For example, a physician who writes a single prescription will by
definition be 100% concentrated on some drug. Thus, including a lot of observations for
very low volume prescribers may lead to unstable or misleading results. We also emphasize
that a threshold of 20 prescriptions is equivalent to two patients filling prescriptions for 10
months/year. This reduced sample of 7,399 accounts for 83% of all antipsychotic
prescriptions among the 24,206 physicians in our sample in 2007. Sensitivity analyses
including the larger sample yielded qualitatively similar results. We linked prescribing data
to information on physician characteristics from the American Medical Association (AMA)
Masterfile(26).
We examined prescribing patterns for six orally-administered second generation
antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and
aripiprazole). Aripiprazole was launched late in 2002 and few physicians in our sample
prescribed it that year; thus, we do not report use of aripiprazole separately in some
analyses. We also examined prescribing of two oral first-generation antipsychotics:
haloperidol, the most commonly prescribed first-generation antipsychotic during our study
period, and perphenazine, the only first-generation antipsychotic included in CATIE. We
combined other first-generation antipsychotics into a single group. Prescriptions for
reformulations (e.g., Zyprexa Zydis) were merged with the original ingredient (e.g.,
olanzapine).
Dependent variables
We analyzed trends in three aspects of prescribing behavior in this longitudinal cohort. First,
we measured the concentration of a physician's prescribing by constructing a Herfindahl
index, a metric traditionally used by economists to characterize the degree of competition in
a market. Here we use it to describe the diversity of a physician's prescribing of
antipsychotics to her patient population. The index is constructed as
where si is the share of prescriptions for drug i in the antipsychotic market, and N is the
number of drugs in the antipsychotic market. The smallest possible value of H is 1/N while
the largest is 1 – these correspond to prescribing each drug with the same frequency and to
only prescribing one drug, respectively. An important point is that H is dependent on the
volume of a physician's prescribing (e.g., H = 1 by definition if they write a single
prescription), which is why we exclude physicians prescribing fewer than 20 prescriptions
from our primary analysis. We hypothesized that physicians would reduce the concentration
of their prescribing in response to evidence of differential side effects. Second, we
quantified changes in the specific drugs most preferred by physicians between 2002 and
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2007. Specifically, for each physician we identified the drug with the most prescriptions
filled in 2002 and then in 2007, yielding estimates of the proportion of physicians revealing
stable (or unstable) preferences over time. Third, we assessed changes in the proportion of
physicians with any prescriptions for each drug in 2002 vs. 2007. We hypothesized that
physicians may have changed not only their preferences for but also their general use of
specific agents based on risk of metabolic effects, potentially reducing use of drugs with the
highest risk (olanzapine and clozapine), increasing use of drugs with intermediate risk
(risperidone and quetiapine), and low risk (aripiprazole and ziprasidone)(12). We also
examined whether physicians increased their use of lower-cost agents (first-generation
antipsychotics) following evidence that these agents were cost-effective relative to second
generation antipsychotics(27).
Key explanatory variables
We were interested in determining whether changes in prescribing behavior differed by
physician specialty and prescribing volume. We classified physicians based on specialty into
2 groups: psychiatry (general, child and adolescent, and geriatric), vs. ‘other,’ which
included neurologists (general and child), pediatricians, and physicians trained in internal
medicine, family medicine, family practice, and general practice. General practitioners and
other non-psychiatrist specialists were considered as a single group because they behaved
similarly on the prescribing practices we observed. To assess prescribing volume, which
may serve as a proxy for a physicians' experience prescribing antipsychotics or for the
prevalence of severe mental illness among their patients, physicians were classified
according to the total number of antipsychotic prescriptions their patients filled in 2001, the
year before the start of the study period. Physicians with prescribing volume above the 50th
percentile were considered high volume prescribers. We included a dummy variable in the
concentration analysis for the 1.8% of physicians whose patients did not fill any
antipsychotic prescriptions in 2001 for whom we could not estimate baseline antipsychotic
volume.
Covariates
We included as covariates physician sex; age in 2002; practice setting (solo practice, two-
person, other (e.g., locum tenens, medical school, inpatient attending only), or no
classification available, with group practice as the reference category); whether the
physician practiced in a hospital setting part- or full-time; whether the physician attended a
medical school ranked in the top 25 by the 2010 US News and World Report; and whether
the physician graduated from a foreign medical school, the latter to explore any differences
in physicians who completed medical education in the U.S. vs. other countries where
preferences for or availability of specific agents may have differed. As a potential proxy for
less contact with the pharmaceutical industry we included an indicator of whether the
physician requested that the AMA withhold their information from pharmaceutical sales
representatives. State fixed effects were included to account for time-invariant geographic
variation in prescribing practices(28) including Medicaid program restrictions on some
antipsychotics in some states(15).
Analyses
To examine the concentration of antipsychotic prescribing we used generalized estimating
equations (GEE) to account for repeated measurements made on the same physician each
year. We used a gamma distribution with a log link function due to the skewed distribution
of the Herfindahl index in our sample. We tested for differences in changes in the physician-
level Herfindahl over time by specialty and/or volume by including three-way interaction
terms between specialty, volume and time (yearly indicators), and the three two-way
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interaction terms for these variables. In addition to these variables, the model adjusted for
the other covariates listed above.
To explore the stability of preferences over time, we calculated the proportion of physicians
preferring each drug (i.e., writing more prescriptions for it than for any other agent) in 2002.
We then calculated the proportion still preferring that agent in 2007 and conducted a test of
proportions by drug.
Finally, we describe changes in the unadjusted rate of physicians prescribing of each drug to
any of their patients in 2002 and in 2007.
Results
Characteristics of study sample
Of the 7,399 sample physicians who regularly prescribed antipsychotics from 2002-2007,
2,437 were psychiatrists and 4,962 were in other specialties (4,398 general practitioners and
564 neurologists or pediatricians) (Table 1). Psychiatrists were more likely to be female, age
50 or older, and solo practitioners than physicians in other specialties. Psychiatrists' mean
annual antipsychotic prescribing volume was 7 times that of physicians in other specialties
(649 vs. 86 for general practitioners and other specialists).
Concentration of prescribing
Antipsychotic prescribing was highly concentrated in physicians' preferred agents. The
unadjusted mean Herfindahl index for physicians was .33 in 2002 and .29 in 2007.
Physicians in non-psychiatric specialties below the median antipsychotic prescribing volume
had the most concentrated prescribing with an unadjusted Herfindahl of .36 compared to
psychiatrists prescribing a high volume of antipsychotics who had a Herfindahl of .18.
Our initial model included the three-way interaction between specialty, volume and time and
the three two-interactions involving the same variables. Because the third-order interaction
explained almost no variation in the data we removed it and refit the model with the two-
way interactions. We found two interactions, one between specialty and time and one
between specialty and volume, were highly significant. Table 2 displays the results from the
GEE model examining the effects of various provider characteristics on the concentration of
antipsychotic prescribing.
The coefficients comprising the specialty by time interaction revealed that the concentration
of psychiatrists has decreased over time and in a manner that is consistent across high and
low volume prescribers. Specifically, the Herfindahl index decreased (i.e., prescribing is less
concentrated) across time for psychiatrists relative to non-psychiatrists. For example, in
2002 the concentration of prescribing by psychiatrists was 4.92% lower than by non-
psychiatrists with the same volume while in 2007 the concentration of psychiatrists was
10.52% lower than that of non-psychiatrists of the same volume (p < .001). The interaction
between specialty and volume reveals that antipsychotic prescribing volume was also
strongly associated with concentration after controlling for other factors and that its effect
depends on specialty. Specifically, in the same year, high volume psychiatrists had a
Herfindahl 44.69% lower that of low volume physicians in other specialties (p<.001) while
low volume psychiatrists had a Herfindahl 4.92% lower that of low volume prescribers in
other specialties (both cases p < 0.001).
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Changes in preferred antipsychotics
Figure 1 displays the dramatic changes in physicians' preferred agents between 2002 and
2007. In 2002, few physicians favored a first-generation antipsychotic, with only 3.7%
preferring haloperidol, .6% perphenazine, and 23.8% one of the other first-generation
antipsychotics. Among second generation antipsychotics, more than two thirds of physicians
favored risperidone (30.2%), olanzapine (29.9%), or quetiapine (9.5%), whereas only 1.8%
preferred clozapine, and .5% ziprasidone in 2002.
By 2007, the vast majority of physicians shifted preferences to a different drug than that
preferred in 2002 (all differences significant at p<.001-level) (Figure 1). Among the first-
generation antipsychotics, even fewer physicians favored haloperidol (2%) or perphenazine
(0.5%) in 2007 than in 2002. Half of the second generation antipsychotics experienced
substantial reductions in the share of physicians preferring them. Olanzapine saw the largest
decline in the share of physicians preferring it (from 29.9% to 10.3%), retaining only 16.4%
of physicians who preferred it in 2002. Risperidone also lost a large share of physicians
preferring it, from 30.2% of physicians in 2002 to 23.1% in 2007. Clozapine was the
preferred agent for an even smaller share of physicians in 2007 (0.9%) than in 2002.
The antipsychotic experiencing the biggest gain was quetiapine -- the fifth of six second
generation antipsychotics to be introduced -- which saw a more than four-fold increase
(from 9.4% to 44.5%) in the share of physicians preferring it. Ziprasidone and aripiprazole
also saw increases in the share of physicians preferring them although the absolute share
was low; only 1.3% and 4.1% of physicians preferred ziprasidone and aripiprazole,
respectively.
Figure 2 highlights the particularly dramatic shift in physicians' observed preferences among
the 2,215 physicians who favored olanzapine above other antipsychotics in 2002. Over half
(52.8%) of all prescriptions filled by patients of these physicians were for olanzapine in
2002. However, beginning in the second quarter of 2003 (long before CATIE results were
released in 2005 and even before the FDA warning about metabolic effects), these
physicians reduced their use of olanzapine such that by 2007, it accounted for only 17.8% of
their prescriptions. These physicians shifted most of their prescribing to quetiapine and
risperidone, which in 2007 accounted for 33.2% and 25.3% of prescriptions, respectively.
Changes in any prescribing of specific antipsychotics
From 2002 to 2007, the share of physicians with any prescribing of the two first-generation
antipsychotics in their practice dropped slightly from 56% to 49% for haloperidol and from
20% to 19% for perphenazine (Figure 3). Among the second generation antipsychotics, the
share of physicians prescribing olanzapine and risperidone to any of their patients decreased,
with the largest decline occurring for olanzapine (from 87% to 76%). The share of
physicians prescribing any quetiapine, ziprasidone, and clozapine increased, with the largest
increase for quetiapine (from 66% to 92% of physicians prescribing it). All of these changes
were statistically significant at the p<.001 level.
Discussion
We report three key findings. First, physicians' reliance on a preferred antipsychotic agent,
as measured by the concentration of their prescribing, declined between 2002 and 2007
particularly among psychiatrists. Second, there are clear differences by specialty and
prescribing volume in the concentration of a physician's antipsychotic prescribing. Third,
there were substantial changes in which antipsychotic agent physicians preferred. These
findings have a number of implications for clinicians, researchers, and policy makers.
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We measured changes in the concentration of prescribing in the wake of high-profile FDA
safety warnings, consensus statements issued from professional societies, a landmark
comparative effectiveness study, expanded approval of new indications and off-label use,
highly-publicized litigation against second generation antipsychotic manufacturers(29), and
policy changes regarding coverage of these drugs. We hypothesized that evidence of
substantial heterogeneity in risk profiles might have induced physicians to diversify their
choice of agent, and we find evidence of this effect, particularly among psychiatrists. The
rise in antipsychotic polypharmacy during this period may have increased the diversity of
agents prescribed(30). We found a mean Herfindahl index of .27 to .33 depending on the
year, which is slightly higher than that reported for antidepressants, suggesting greater
concentration of antipsychotic than antidepressant prescribing(22, 24). Customizing drug
treatment to individual patients requires more time and communication with patients, and
can impose a significant cognitive burden on physicians(19). To reduce these costs,
physicians often rely heavily on a few drugs per class,(19-21, 23, 24, 31) an approach often
reinforced in clinical pharmacology education(32). However, heavy reliance by physicians
on a few antipsychotics could be problematic for patients because of heterogeneity in their
side effects.
That psychiatrists were so much less concentrated (more diversified) in their choice of
antipsychotic suggests the capacity to customize treatment may vary by the degree of
specialization, by experience, or with the severity of patient illness(33, 34). Psychiatrists
generally focus their prescribing on a few therapeutic categories, whereas psychiatric
medication makes up a smaller (if growing) part of primary care physicians' prescribing(35).
Variability in concentration may also be related to inter-specialty differences in the clinical
indications for use and/or patient severity. Importantly, the effects of specialty remained
strong even after adjusting for volume differences. Given the dramatic expansion in
antipsychotic prescribing in primary care settings, it is important to better understand these
specialty differences,(36, 37) and their implications for quality of pharmacotherapy for
mental disorders(38-40).
Even after controlling for specialty, antipsychotic prescribing volume was negatively
associated with concentration, suggesting that physicians' ability to diversify medication
choice may increase with experience prescribing antipsychotics. Perhaps the costs of
customizing treatment are reduced when spread across a large number of patients. Thus, a
physician with only a few patients might be less inclined to diversify and require definitive
clinical evidence before starting a patient on a new drug. While a volume-quality
relationship is well-documented in health care generally, we are unaware of evidence of
such a relationship for prescribing(31).
Preferences for specific drugs changed dramatically. The antipsychotic experiencing the
greatest decline was olanzapine, a change that began two years before CATIE results were
published. The share of physicians prescribing any of the two first-generation antipsychotics
we studied (haloperidol and perphenazine) also fell. The antipsychotic with the greatest
increase in the share of physicians preferring it was quetiapine, whose share increased from
9% to 45%. How does one explain these shifts in physician preferences? We are unable to
tease out the effects on prescribing behavior of any single event because all physicians are
equally ‘exposed’ and we lack a comparison group. However, four important factors warrant
discussion. First, metabolic effects were arguably one of the most salient issues influencing
antipsychotic prescribing. Yet, the shifts in observed physician preferences cannot be
entirely explained by these differences. Physicians increased use of one drug with
intermediate risk (quetiapine), but not the other (risperidone), and a drug with low metabolic
risk (ziprasidone) actually experienced a reduction in physician prescribing. Second, some
shifts in preferences may have been driven by off-label use (e.g., quetiapine for sleep
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disturbances)(3, 41). Third, the reduction in use of first-generation antipsychotics and
clozapine suggests that physicians either were unaware of or not influenced by evidence of
the cost-effectiveness of first-generation antipsychotics relative to second generation
antipsychotics(27), and the greater effectiveness of clozapine relative to other second
generation antipsychotics for treatment-resistant patients(42). Fourth, antipsychotics are
heavily promoted by the pharmaceutical industry mostly through sales representatives,
sponsorship of professional meetings, medical journal ads, and free samples(43) all of which
can have a significant effect on physician prescribing preferences(44-46). Unfortunately,
data on the exposure of individual physicians to promotion is not available. Notably,
aripiprazole has been advertised to consumers as well, ranking 5th in direct-to-consumer
advertising spending across all prescriptions drugs in 2010(43).
Our study has several limitations. First, we lack information on the patients filling the
prescriptions, and therefore cannot identify the reason for antipsychotic use, determine the
severity of illness, or distinguish between new treatment starts and patients who are stable
on a medication. Second, while we selected our time period to coincide with key events such
as FDA warnings and the CATIE trial, other underlying factors may have had an effect on
prescribing behavior and we cannot infer a causal relationship between the release of studies
or warnings and prescribing decisions. Third, we have data only on prescriptions filled
through retail outlets (i.e., no mail order programs or long-term care facilities) and therefore
do not observe changing preferences for drugs dispensed in these settings. Furthermore, to
the extent that we only have data on prescriptions filled (not all those written), our results
are confounded by factors affecting patient decisions to fill prescriptions. However, we do
not expect discrepancies between prescriptions written and filled to differ systematically by
drug. Finally, we are unable to adjust for some important influences on prescribing behavior
such as manufacturer promotional efforts, which may vary by specialty, health systems
within which physicians practice, and payers which may shape physician preferences
through formularies and utilization management tools such as prior authorization (15, 16).
Conclusions
Physician preferences for specific antipsychotics changed dramatically from 2002 to 2007.
Some physicians remained heavily concentrated in their antipsychotic prescribing whereas
others diversified their choice of agent, with striking differences by specialty.
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Figure 1. Changes in Physicians' preferred antipsychotic medication between 2002-2007
Notes:
Preferred agent is the product for which the physician's patients fill the most prescriptions in
a given year
Source: IMS Xponent, 2001-2007, IMS Health, Inc.
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Figure 2. Among physicians preferring olanzapine in 2002, the share of prescriptions for
olanzapine and for other antipsychotics, 2002-2007
Notes: Graph shows quarterly share of prescriptions written for each drug among 2,215
physicians who favored olanzapine above other antipsychotics in 2002.
Source: IMS Xponent, 2001-2007, IMS Health, Inc.
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Figure 3. Proportion of physicians prescribing any of select antipsychotics
Source:
IMS Xponent, 2001-2007, IMS Health, Inc.
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